$18.13
0.321.8%
Last update: Oct 6, 3:47 PM
$17.93
0.120.67%
Takeda Pharmaceutical Co Ltd
TAKNYSE
Takeda Pharmaceutical Co (TAK) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Takeda Pharmaceutical Co (TAK) last issued guidance on July 30, 2026 for fiscal year 2026. The company guided earnings per share in the range of $3.01 - $3.01, compared to a consensus EPS estimate of $1.57. Takeda Pharmaceutical Co also guided revenue in the range of $29.59B - $29.59B for the period.
Compared to prior guidance, Takeda Pharmaceutical Co maintained its EPS outlook from a previous range of $3.01 - $3.01. On the revenue side, the company maintained its revenue forecast from a prior range of $29.59B - $29.59B.
Takeda Pharmaceutical Co has issued 16 guidance updates between October 27, 2022 and July 30, 2026. During this period, the company raised its outlook 7 times and lowered it 6 times, providing investors with insight into management's evolving expectations.
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.39 | $0.21 | $0.55 | $0.44 |
| Actual | $0.48 | $0.28 | $0.47 | $0.43 |
| Surprise | +23.8% | +35.2% | -13.6% | -2.27% |
| Revenue | ||||
| Estimate | $7.06B | $7.05B | $8.53B | $8.08B |
| Actual | $7.65B | $6.98B | $7.60B | $7.52B |
| Surprise | +8.42% | -1.02% | -10.9% | -6.93% |
| Metric | Q2 '26E | Q3 '26E | Q4 '26E | Q1 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.45 | $0.51 | $0.45 | $0.54 |
| Revenue | ||||
| Consensus | $7.19B | $7.65B | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q1 | Jul 30, 2026 | $0.48 | $0.39 | 23.8 % |
| Q4 | May 13, 2026 | $0.28 | $0.21 | 35.2 % |
| Q3 | Jan 29, 2026 | $0.48 | $0.55 | -13.6 % |
| Q2 | Oct 30, 2025 | $0.43 | $0.44 | -2.27 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q1 | Jul 30, 2026 | $7.65B | $7.06B | 8.42 % |
| Q4 | May 13, 2026 | $6.98B | $7.05B | -1.02 % |
| Q3 | Jan 29, 2026 | $7.60B | $8.53B | -10.9 % |
| Q2 | Oct 30, 2025 | $7.52B | $8.08B | -6.93 % |
